Cue Biopharma (CUE) Corporate presentation summary

Strategic focus and pipeline overview

• Focused on developing functional cures for immunological disorders with high unmet need, leveraging precision immuno-engineering.

• Portfolio includes CUE-221 (anti-IgE for allergic diseases, Phase 2) and CUE-401 (bifunctional IL-2/TGF-β for autoimmune diseases, advancing to Phase 1).

• Additional programs include CUE-501 (B cell depletion) and the CUE-100 series (solid tumors), with partnerships and milestone/royalty opportunities.

• Company is funded to reach key clinical milestones, with a complementary team supporting strategic growth.

CUE-221: Novel anti-IgE therapy

• Dual mechanism of action: neutralizes free IgE and downregulates IgE synthesis, outperforming existing therapies.

• Demonstrates higher binding affinity and slower dissociation than omalizumab, with robust preclinical and clinical data.

• Phase 2 study in chronic spontaneous urticaria (CSU) underway, with data readout expected by end of 3Q 2026.

• Pipeline-in-a-product potential for multiple allergic diseases, including food allergy, atopic dermatitis, and asthma.

• Well-tolerated safety profile and clinically meaningful improvements in symptom scores.

Market opportunity and unmet need

• Food allergy and other IgE-driven diseases represent large, underserved markets with millions affected globally.

• Existing therapies like omalizumab have limitations, including eligibility restrictions and incremental improvements from emerging competitors.

• CUE-221 targets significant unmet needs across allergic diseases, with potential for best-in-class efficacy.